SMC Update - May 2019
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Cariprazine (Reagila®) has been accepted for restricted use in the treatment of schizophrenia in adult patients. The restriction limits use to second-line therapy in patients where predominantly negative symptoms have been identified as an important feature.
Latanoprost and timolol (Fixapost®) has been accepted for restricted use for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. The restriction limits use to patients who have proven sensitivity to preservatives.
Doxylamine succinate and pyridoxine hydrochloride (Xonvea®) has been rejected for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. The submitting company did not present a sufficiently robust clinical or economic analysis to gain acceptance by SMC.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
| « CKS Updates - April 2019 | Drug Safety Update - May 2019 » |
Leave a Comment